Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

BACKGROUND: A vaccine against HIV is widely considered the most effective and sustainable way of reducing new infections. We evaluated the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian volunteers previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Joachim, Agricola, Bauer, Asli, Joseph, Sarah, Geldmacher, Christof, Munseri, Patricia J., Aboud, Said, Missanga, Marco, Mann, Philipp, Wahren, Britta, Ferrari, Guido, Polonis, Victoria R., Robb, Merlin L., Weber, Jonathan, Tatoud, Roger, Maboko, Leonard, Hoelscher, Michael, Lyamuya, Eligius F., Biberfeld, Gunnel, Sandström, Eric, Kroidl, Arne, Bakari, Muhammad, Nilsson, Charlotta, McCormack, Sheena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871571/
https://www.ncbi.nlm.nih.gov/pubmed/27192151
http://dx.doi.org/10.1371/journal.pone.0155702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871571/
https://www.ncbi.nlm.nih.gov/pubmed/27192151
http://dx.doi.org/10.1371/journal.pone.0155702

Ejemplares similares